Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Debt (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Total Debt for 7 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Debt fell 67.69% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 67.69% decrease, with the full-year FY2025 number at $2.7 million, down 67.69% from a year prior.
  • Total Debt was $2.7 million for Q4 2025 at Beam Therapeutics, up from $1.2 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $85.4 million in Q2 2021 to a low of $1.2 million in Q3 2025.
  • A 5-year average of $21.6 million and a median of $13.2 million in 2023 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: skyrocketed 596.19% in 2021, then tumbled 85.81% in 2025.
  • Beam Therapeutics' Total Debt stood at $42.2 million in 2021, then plummeted by 56.64% to $18.3 million in 2022, then plummeted by 40.98% to $10.8 million in 2023, then decreased by 22.22% to $8.4 million in 2024, then tumbled by 67.69% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Total Debt are $2.7 million (Q4 2025), $1.2 million (Q3 2025), and $3.9 million (Q2 2025).